Vertex Pharmaceuticals (VRTX) Minority Interest (2011 - 2018)

Vertex Pharmaceuticals has reported Minority Interest for 8 years, with the latest figure at $28.4 million in Q3 2018.

• On a quarterly basis, Minority Interest rose 133.13% year-over-year to $28.4 million in Q3 2018; TTM through Sep 2018 was $28.4 million, a 133.13% increase from a year earlier, with the FY2017 full-year figure at $13.7 million, down 92.44% from the prior year.
• Minority Interest was $28.4 million for Q3 2018 at Vertex Pharmaceuticals, down from $28.7 million in the prior quarter.
• The five-year high for Minority Interest was $196.0 million in Q2 2017, with the low at $12.2 million in Q3 2017.
• Average Minority Interest over 5 years is $106.9 million, with a median of $153.5 million recorded in 2015.
• The sharpest annual moves came in 2016 and 2017: Minority Interest jumped 654.87% in 2016, then tumbled 93.49% in 2017.
• Over 5 years, Minority Interest stood at $21.2 million in 2014, then jumped by 625.6% to $153.7 million in 2015, then climbed by 18.19% to $181.6 million in 2016, then plunged by 92.44% to $13.7 million in 2017, then jumped by 106.64% to $28.4 million in 2018.
• The last three Minority Interest figures came in at $28.4 million (Q3 2018), $28.7 million (Q2 2018), and $29.8 million (Q1 2018), per Business Quant data.